Last reviewed · How we verify
Thymoglobuline Genzyme
Thymoglobuline is a polyclonal antithymocyte globulin (ATG) that depletes T lymphocytes by binding to multiple T-cell antigens and triggering their destruction.
Thymoglobuline is a polyclonal antithymocyte globulin (ATG) that depletes T lymphocytes by binding to multiple T-cell antigens and triggering their destruction. Used for Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic), Treatment of acute rejection episodes in transplant recipients, Severe aplastic anemia.
At a glance
| Generic name | Thymoglobuline Genzyme |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Thymoglobuline is produced by immunizing rabbits with human thymocytes, generating a polyclonal antibody preparation that targets multiple epitopes on T cells. These antibodies bind to T-cell surface antigens and promote T-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct induction of apoptosis. This profound immunosuppression is used to prevent or treat acute rejection in transplantation and to treat certain T-cell malignancies and severe aplastic anemia.
Approved indications
- Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic)
- Treatment of acute rejection episodes in transplant recipients
- Severe aplastic anemia
- T-cell lymphomas and leukemias
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infusion reactions
- Infection (opportunistic)
- Rash
- Lymphadenopathy
Key clinical trials
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- 1 vs 7 RATG Infusions in Renal Transplantation
- ATG Plus Low-dose PT-Cy for GVHD Prevention (PHASE3)
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (PHASE1)
- Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome (PHASE2)
- Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia (PHASE2)
- The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymoglobuline Genzyme CI brief — competitive landscape report
- Thymoglobuline Genzyme updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI